Meatable Acquires Uncommon Bio’s Cultivated Meat Platform in Landmark Deal
Dutch cultivated meat pioneer Meatable has announced the acquisition of Uncommon Bio’s cultivated meat platform, a move that promises to reshape the trajectory of cellular agriculture.
The financial details of the deal remain undisclosed, but the agreement covers key technology, multiple intellectual property assets and cell lines, as well as Uncommon’s staff.
A Strategic Shift for Uncommon Bio
Uncommon Bio, based in Cambridge, has chosen to pivot away from cultivated meat and direct its focus towards therapeutics. In making the transition, the company sought a partner capable of continuing its scientific legacy in food innovation.
The company’s CEO expressed that they are incredibly proud of what they have built at Uncommon Bio – a legacy of innovation and bold thinking in cultivated meat. After deciding to focus on therapeutics, they wanted to find the best home for their technology, and it’s exciting to see Meatable carry their work forward and apply it at scale.
What’s more, they look forward to continued collaboration and to watching their global impact in the years ahead.
Expanding Meatable’s Multi-Platform Offering
The acquisition introduces Uncommon’s non-GMO mRNA reprogramming and saRNA differentiation technologies into Meatable’s portfolio, creating a true multi-platform cultivated meat technology offering.
This expanded capability is expected to accelerate product development, shorten time-to-market, and streamline navigation through international regulatory frameworks. Crucially, the non-GMO status of Uncommon’s technology, combined with its regulatory-ready dossier, is set to open doors for quicker approvals across multiple regions.
Raising the Bar for Cultivated Meat Production
Meatable’s leadership framed the acquisition as more than just a business move. The Meatable CEO commented that this is more than a strategic step – it sets a new standard for cultivated meat production.
By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale. This enables them to support the meat industry with a stable, secure, and future-proof supply of species such as pork, beef, lamb, and poultry, ensuring continuity and resilience in increasingly uncertain times.
The integration of Uncommon Bio’s technology also accelerates development in areas such as cultivated chicken and lamb – two categories that Meatable has identified as high-priority markets.
At the same time, the deal enriches Meatable’s intellectual property portfolio, strengthening its position as a technological leader in the cultivated meat sector.
Investor Confidence and Industry Validation
The chief technology officer of Meatable highlighted another significant benefit of the deal: the calibre of investors behind Uncommon’s innovations. The value of the IP is strengthened by the calibre of investors who supported Uncommon’s mission from the start.
They are proud to carry forward technology that has earned the trust of such respected backers as Apollo Projects and Lower Carbon Capital, further fuelling their path to success at scale.
Investor confidence and proven backing lend additional weight to Meatable’s ambitions. The company has already demonstrated its leadership credentials, having hosted the first-ever legally approved cultivated meat tasting in the EU last year, offering guests the chance to sample its cultivated pork sausages.
Conclusion: A Defining Moment for Cultivated Meat
The acquisition of Uncommon Bio’s cultivated meat platform represents a defining moment for Meatable and for the broader cultivated meat industry. By combining scientific expertise, intellectual property, and complementary technologies, Meatable is now uniquely positioned to fast-track innovation, accelerate regulatory approvals, and diversify product development.
As Uncommon Bio shifts its sights to therapeutics, Meatable inherits a legacy of bold innovation and carries it forward on a global scale. The result is a strengthened commitment to delivering high-quality cultivated meat, supporting food security, and redefining the future of protein.
News Credits: Meatable acquires Uncommon Bio’s cultivated meat platform
Things you may also like:
- Upperton Pharma Solutions and Oxford Team Up to Pioneer Oral Vaccine Delivery
- Tiffin Sandwiches Bolsters Growth with Acquisition of Love Bites
- UK Gov and Eli Lilly Launch £85M Drive to Transform Obesity Care